Open access
2026
Unlocking New Therapeutic Potentials: An MIS-Driven Framework for Repurposing FDA-Approved Drugs
By enabling researchers to resume trials at advanced stages (Phase II/III), this model offers a strategic pathway to reduce R&D expenditures from billions to millions and accelerate market entry by 5–7 years.
A. F. M. Nazmus Sadat, Tanjina Piash, M. Al Hussain et al.
· International journal of res... · 0 citations